Vor Biopharma Inc (VOR) Stock Forecast & Price Target
Vor Biopharma Inc · NASDAQ
$19.44+0.18 (+0.93%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Vor Biopharma Inc, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $18.00 to $64.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $40.43 sits 108% above the current $19.44. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.77 next quarter toward $-3.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Vor Biopharma Inc.
As of Jul, 7 of 8 firms rate VOR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VOR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.77
Range $-0.95 – $-0.59 · 2 analysts · -99% YoY
Next period, 2 analysts expect Vor Biopharma Inc to earn $-0.77 a share (range $-0.95 – $-0.59), versus $-121.63 a year earlier. Full-year consensus is $-6.90, growing to $-3.74 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Vor Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VOR.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Hold
$6.00-69.1% to target
Overall win rate
50%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Buy
$40.00+105.8% to target
Overall win rate
46%
+ Follow
#3
David Nierengarten
Wedbush · Rank #115
Hold
$0.40-97.9% to target
Overall win rate
41%
+ Follow
#4
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$31.00+59.5% to target
Overall win rate
37%
+ Follow
#5
JA
Jack Allen
Baird
Buy
$46.00+136.6% to target
Coverage
—
+ Follow
VOR stock forecast FAQ
What is VOR's average 12-month price target?+
The 7 analysts with a live target average $40.43 for Vor Biopharma Inc over the next 12 months, ranging from a $64.00 high to a $18.00 low.
Is VOR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VOR?+
The Street-high target is $64.00 (Baird), and the Street-low is $18.00 (Wedbush). The average of all 7 active targets is $40.43.
How many Wall Street analysts cover VOR?+
8 analysts have an active rating on Vor Biopharma Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering VOR?+
Among analysts who currently cover VOR, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Hold with a $6.00 target.
What is Vor Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.77 per share (range $-0.95 – $-0.59) across 2 analysts. Full-year EPS is projected at $-6.90, rising to $-3.74 the following year.
How much revenue is Vor Biopharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VOR lately?+
As of Jul, 7 of 8 firms rate VOR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VOR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
